The comparison of Carfilzomib, and dexamethasone versus pomalidomide-based combination chemotherapy after a 2nd-line therapy in relapsed and refractory multiple myeloma patients

Authors :: Jae-Cheol Jo
Chang-Ki Min
Kihyun Kim
Sung-Hyun Kim
Ho Sup Lee
Ho-Young Yhim
Won Sik Lee
Jae-Young Kwak
Dong-Yeop Shin
Yoo Jin Lee
Ho-Jin Shin
Sung-Soo Park
Ji Yun Lee
Ja Min Byun
Yoon Seok Choi
Ji Hyun Lee
Joon Seong Park
Source :: Clinical Lymphoma Myeloma and Leukemia. 19:e264-e265
Publication Year :: 2019
Publisher :: Elsevier BV, 2019.

Subjects :: Oncology
Cancer Research
medicine.medical_specialty
business.industry
Refractory Multiple Myeloma
Combination chemotherapy
Hematology
Pomalidomide
Carfilzomib
chemistry.chemical_compound
chemistry
Internal medicine
medicine
Line (text file)
business
Dexamethasone
medicine.drug

Full Text Access

Tools